Getting a new therapy to market takes years of work. By the time a product reaches the manufacturing stage, teams have already invested heavily in research, clinical development, regulatory submissions, and production planning—which is why tech transfer can be a frustrating source of delay.
Whether production is moving from development into commercial manufacturing, shifting to a new facility, or being transferred to a CDMO, technology transfer is where years of product knowledge must become a repeatable, scalable manufacturing process. If that handoff isn’t executed well, validation timelines slip, production readiness suffers, and launch dates can move further out.
For pharmaceutical companies facing pressure to bring therapies to market faster, understanding the causes of tech transfer delays has become increasingly important.
RELATED: Why It’s Important to Increase Speed to Market in Life Sciences
What Is Tech Transfer in Pharma?
Technology transfer typically occurs when a drug advances from development into commercial manufacturing, when production moves between sites, or when manufacturing responsibilities shift to a contract development and manufacturing organization (CDMO).
The International Council for Harmonisation (ICH) defines the goal of technology transfer as transferring product and process knowledge between development and manufacturing organizations to support successful product realization and ongoing improvement.
While the definition sounds straightforward, the reality is far more complex. Scientific knowledge accumulated over years of development must be translated into repeatable manufacturing processes that can consistently meet quality standards.
Every step, from raw material specifications to analytical methods and process controls, must be accurately documented and understood by the receiving team. Even minor knowledge gaps can create significant downstream issues.
Why Tech Transfer Is So Difficult
Most launch delays aren’t caused by a single major mistake.
Instead, they happen when small issues compound throughout the transfer process. A missing piece of process knowledge, an unexpected scale-up challenge, or a validation issue can quickly put pressure on timelines that are already tight.
The challenge has become even greater as pharmaceutical companies expand manufacturing networks, open new facilities, and work with global manufacturing partners.
Every receiving site must prove it can consistently manufacture a product according to approved quality standards before commercial production can begin. According to FDA process validation guidance, manufacturers must establish evidence that their processes can consistently deliver quality products.
That’s where many tech transfer programs encounter roadblocks.
The Most Common Causes of Tech Transfer Delays
Even well-planned product launches can run into trouble during tech transfer, especially when critical information, resources, or stakeholders aren’t aligned from the start. Let’s explore some of the common challenges.
Critical Knowledge Gets Lost in the Handoff
Development teams spend years learning how a product behaves. They understand process sensitivities, historical deviations, troubleshooting approaches, and critical quality considerations.
Unfortunately, not all of that knowledge makes its way into formal documentation.
WHO guidance notes that successful technology transfer requires more than transferring documents. Receiving organizations must also demonstrate their ability to successfully perform the transferred process.
When critical information is missing or difficult to interpret, receiving teams often need additional investigations, process studies, and troubleshooting activities before validation can proceed.
Scale-Up Introduces Manufacturing Challenges
A process that performs well at lab or pilot scale may not behave the same way during commercial manufacturing.
Larger batch sizes, different equipment configurations, facility constraints, and operator variability can all influence product quality. These issues often emerge during engineering runs or process qualification activities, when schedule flexibility is already limited.
Additional process development work, manufacturing trials, or equipment adjustments can add weeks or months to commercialization timelines.
Documentation Becomes a Bottleneck
Tech transfer generates an enormous amount of documentation.
Manufacturing records, analytical methods, validation protocols, change controls, equipment qualifications, risk assessments, and training records all need to be complete and aligned.
When information is missing or outdated, quality and validation teams can’t move as quickly as planned. Documentation, validation, qualification, and quality control are all essential components of successful technology transfer programs.
Many organizations underestimate just how much launch risk can come from documentation alone.
Too Many Teams are Working in Silos
Technology transfer isn’t owned by one department.
Manufacturing, quality, validation, engineering, supply chain, regulatory affairs, and process development all play a role in the outcome. When those groups aren’t aligned, decisions take longer, ownership becomes unclear, and timelines suffer.
The ICH Q10 Pharmaceutical Quality System highlights the importance of knowledge management, communication, and quality risk management across the product lifecycle.
Organizations that establish strong governance early are typically much better positioned to keep transfers moving forward.
How Pharma Companies Can Reduce Risk
Organizations that consistently execute successful tech transfers tend to follow similar practices.
Build Manufacturing Into Development Earlier
Engaging manufacturing, validation, and quality teams early helps identify scale-up risks before transfer activities begin.
Earlier collaboration also improves knowledge capture and reduces surprises during later stages of commercialization.
Standardize Documentation and Knowledge Transfer
Structured transfer plans, standardized documentation, and clear communication channels help ensure critical information reaches the right stakeholders.
Effective knowledge management reduces the likelihood that teams will need to recreate work later.
Prioritize Risk Management Before Validation Starts
Risk assessments can help teams identify process vulnerabilities, equipment concerns, data gaps, and resource constraints before they become schedule-impacting issues.
Addressing risks proactively is often significantly less disruptive than addressing them during validation.
Invest in Workforce Readiness
Even the most thoroughly documented transfer will struggle if receiving teams lack the necessary experience.
Training programs, operational support, and specialized expertise help ensure teams are prepared to execute manufacturing processes successfully from day one.
Strong Tech Transfer Requires the Right Support
A successful technology transfer depends on people as much as processes. Manufacturing readiness, validation planning, quality oversight, engineering support, and project execution all play a role in keeping products on track for commercialization.
At Insight Global, we help life sciences organizations strengthen technology transfer programs with specialized talent and functional service solutions. Whether you’re standing up a new facility, transferring production to a manufacturing partner, or preparing a commercial launch, our teams help reduce risk, close capability gaps, and keep critical programs moving forward.
Contact us to get the expertise needed to bring products to market with confidence.
Find Life Sciences Solutions
Questions? Call us toll-free: 855-485-8853
